FDA Approved: TACROLIMUS — Supplemental Application (Biocon Pharma Inc.)

View source ↗

Summary

FDA approved Biocon Pharma Inc.'s supplemental application for tacrolimus, updating labeling to support its use in preventing organ transplant rejection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplant Rejection
• Kidney Transplant Rejection
• Liver Transplant Rejection

Drugs mentioned

• Tacrolimus (Tacrolimus)

Snippet

SUPPL AP for TACROLIMUS (TACROLIMUS)